Non-Hodgkin Lymphoma
Conditions
Keywords
Lymphoma, Cohort, non-Hodgkin
Brief summary
The goal of this infrastructure grant is to establish and maintain a cohort of over 12,000 non-Hodgkin lymphoma (NHL) patients to support broad and cutting-edge research that identifies clinical (including co-morbid diseases), epidemiologic (including lifestyle and other exposures), host genetic, tumor, and treatment factors, as well as the interaction among these factors, on short and long-term outcomes. These efforts will identify new approaches to improve the survival and well-being of NHL patients.
Detailed description
Newly diagnosed non-Hodgkin lymphoma (NHL) patients will be recruited from each center participating in the LEO cohort. At time of consent, participants will be asked to completed several questionnaires collecting health history, current medical and quality of life questions. Patients will also provide a baseline blood sample that will processed locally and stored centrally for future research use. Additionally, consent is given for use of excess clinical tumor tissue for research use.
Interventions
None listed
Sponsors
Emory University
University of Iowa
M.D. Anderson Cancer Center
Washington University School of Medicine
University of Rochester
Weill Medical College of Cornell University
University of Miami
Mayo Clinic
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Newly diagnosed non-Hodgkin Lymphoma (NHL), within 183 days of enrollment * Patients may have been treated as long as initial NHL diagnosis is within 6 months of enrollment * 18 years of age or older
Exclusion criteria
* Lymphoma diagnosis greater than 184 days from date of consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | Short (<5 years), medium (5-10 years), and long-term (>10 years) | Time from date of diagnosis to date of death |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Event Free Survival (EFS) | Short (<5 years), medium (5-10 years), and long-term (>10 years) | Time from date of diagnosis to date of first defined event (disease progression, relapse or re-treatment for lymphoma, or death) |
| Lymphoma Specific Survival (LSS) | Short (<5 years), medium (5-10 years), and long-term (>10 years) | Time from date of diagnosis to date of death due to lymphoma |
Countries
United States
Outcome results
None listed